A class of proteins, known as TMEM16 scramblases, permit rearrangement of lipids in the cell membrane chiefly by thinning the membrane, according to a new model by Weill Cornell Medicine investigators.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, according to a preclinical study by investigators at Weill Cornell Medicine.
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth.
The Weill Cornell Medicine research takes a step toward precision medicine for a type of cancer that disproportionately affects people with African ancestry, an underserved population.
Cornell startup Antithesis Foods and Bactana were awarded NSF small-business grants, as Guard Medical raises $11 million in Series B investments and C2i launches a disease test in Europe.
President Martha E. Pollack joined Deans Augustine M.K. Choi and Barbara Hempstead in conferring degrees on students graduating from Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences, in the first in-person ceremony since the beginning of the COVID-19 pandemic.
Robust collaboration between community partners and Cornell has resulted in more than 2 million COVID-19 tests, saving lives throughout the Finger Lakes region.
Charles R. Lee was one of the university’s most active and generous ambassadors, and a tireless advocate for deeper connections across Cornell’s campuses and alumni communities.
Tumors can force neighboring cells into supporting cancer growth by releasing lactate into their local environment, according to researchers at Weill Cornell Medicine. The findings pave the way for future drug treatments that thwart that defense mechanism to help cancer patients.
